436 Studies Now Enrolling
A double-blind, randomised, placebo-controlled trial evaluating the effect of BI 655064 administered as sub-cutaneous injections, on renal response after one year of treatment, in patients with active lupus nephritis
A study for patients with Lupus Nephritis using the study drug BI 655064.
| Sponsor: | Boehringer Ingelheim |
| Enrolling: | Male and Female Patients |
| Study Length: | 60 Weeks |
| Clinic Visits: | 18 |
| IRB Number: | AAAQ6365 |
| U.S. Govt. ID: | NCT02770170 |
| Contact: | Anca Askanase MD MPH: 212-305-0856 / ada20@cumc.columbia.edu |
Additional Study Information:
This study is for men and women who have been diagnosed with Lupus Nephritis. In this study, doctors will evaluate the effectiveness of the investigational medication administered as sub-cutaneous injections for Lupus Nephritis over a 52 week period. All study-related visits, tests, and medications will be provided to you at no cost.
This study is closed
Do You Qualify?
| Have you been diagnosed with Lupus Erythematosus (SLE)? | Yes | No |
| Have you been recently diagnosed with Lupus Nephritis and received a renal biopsy within the last three months? | Yes | No |
| Should you qualify, would you be ready and able to use highly effective methods of birth control? | Yes | No |
| Are you pregnant, nursing, or plan to become pregnant while in the trial? | Yes | No |